1742 related articles for article (PubMed ID: 29151692)
1. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease.
Kostas A; Siakavellas SI; Kosmidis C; Takou A; Nikou J; Maropoulos G; Vlachogiannakos J; Papatheodoridis GV; Papaconstantinou I; Bamias G
World J Gastroenterol; 2017 Nov; 23(41):7387-7396. PubMed ID: 29151692
[TBL] [Abstract][Full Text] [Related]
2. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China.
Chen JM; Liu T; Gao S; Tong XD; Deng FH; Nie B
World J Gastroenterol; 2017 Dec; 23(46):8235-8247. PubMed ID: 29290660
[TBL] [Abstract][Full Text] [Related]
4. Practical fecal calprotectin cut-off value for Japanese patients with ulcerative colitis.
Urushikubo J; Yanai S; Nakamura S; Kawasaki K; Akasaka R; Sato K; Toya Y; Asakura K; Gonai T; Sugai T; Matsumoto T
World J Gastroenterol; 2018 Oct; 24(38):4384-4392. PubMed ID: 30344422
[TBL] [Abstract][Full Text] [Related]
5. Low Fecal Calprotectin Correlates with Histological Remission and Mucosal Healing in Ulcerative Colitis and Colonic Crohn's Disease.
Zittan E; Kelly OB; Kirsch R; Milgrom R; Burns J; Nguyen GC; Croitoru K; Van Assche G; Silverberg MS; Steinhart AH
Inflamm Bowel Dis; 2016 Mar; 22(3):623-30. PubMed ID: 26829408
[TBL] [Abstract][Full Text] [Related]
6. Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year.
Guidi L; Marzo M; Andrisani G; Felice C; Pugliese D; Mocci G; Nardone O; De Vitis I; Papa A; Rapaccini G; Forni F; Armuzzi A
Dig Liver Dis; 2014 Nov; 46(11):974-9. PubMed ID: 25096964
[TBL] [Abstract][Full Text] [Related]
7. Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: a plea for deep remission.
Mooiweer E; Severs M; Schipper ME; Fidder HH; Siersema PD; Laheij RJ; Oldenburg B
J Crohns Colitis; 2015 Jan; 9(1):50-5. PubMed ID: 25518048
[TBL] [Abstract][Full Text] [Related]
8. From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting.
Mumolo MG; Bertani L; Ceccarelli L; Laino G; Di Fluri G; Albano E; Tapete G; Costa F
World J Gastroenterol; 2018 Sep; 24(33):3681-3694. PubMed ID: 30197475
[TBL] [Abstract][Full Text] [Related]
9. Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases.
Nancey S; Boschetti G; Moussata D; Cotte E; Peyras J; Cuerq C; Haybrard J; Charlois AL; Mialon A; Chauvenet M; Stroeymeyt K; Kaiserlian D; Drai J; Flourié B
Inflamm Bowel Dis; 2013 Apr; 19(5):1043-52. PubMed ID: 23511035
[TBL] [Abstract][Full Text] [Related]
10. Low fecal calprotectin predicts clinical remission in Crohn's disease patients: the simple answer to a challenging question.
Monteiro S; Dias de Castro F; Leite S; Moreira MJ; Cotter J
Scand J Gastroenterol; 2019 Jan; 54(1):49-54. PubMed ID: 30663515
[TBL] [Abstract][Full Text] [Related]
11. Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis?
García-Sánchez V; Iglesias-Flores E; González R; Gisbert JP; Gallardo-Valverde JM; González-Galilea A; Naranjo-Rodríguez A; de Dios-Vega JF; Muntané J; Gómez-Camacho F
J Crohns Colitis; 2010 Jun; 4(2):144-52. PubMed ID: 21122498
[TBL] [Abstract][Full Text] [Related]
12. Raised faecal calprotectin is associated with subsequent symptomatic relapse, in children and adolescents with inflammatory bowel disease in clinical remission.
Diederen K; Hoekman DR; Leek A; Wolters VM; Hummel TZ; de Meij TG; Koot BG; Tabbers MM; Benninga MA; Kindermann A
Aliment Pharmacol Ther; 2017 Apr; 45(7):951-960. PubMed ID: 28138990
[TBL] [Abstract][Full Text] [Related]
13. Fecal calprotectin correlated with endoscopic remission for Asian inflammatory bowel disease patients.
Lin WC; Wong JM; Tung CC; Lin CP; Chou JW; Wang HY; Shieh MJ; Chang CH; Liu HH; Wei SC;
World J Gastroenterol; 2015 Dec; 21(48):13566-73. PubMed ID: 26730169
[TBL] [Abstract][Full Text] [Related]
14. Fecal Calprotectin Levels Predict Histological Healing in Ulcerative Colitis.
Patel A; Panchal H; Dubinsky MC
Inflamm Bowel Dis; 2017 Sep; 23(9):1600-1604. PubMed ID: 28590341
[TBL] [Abstract][Full Text] [Related]
15. Fecal calprotectin in assessing inflammatory bowel disease endoscopic activity: a diagnostic accuracy meta-analysis.
Rokkas T; Portincasa P; Koutroubakis IE
J Gastrointestin Liver Dis; 2018 Sep; 27(3):299-306. PubMed ID: 30240474
[TBL] [Abstract][Full Text] [Related]
16. Serial semi-quantitative measurement of fecal calprotectin in patients with ulcerative colitis in remission.
Garcia-Planella E; Mañosa M; Chaparro M; Beltrán B; Barreiro-de-Acosta M; Gordillo J; Ricart E; Bermejo F; García-Sánchez V; Piqueras M; Llaó J; Gisbert JP; Cabré E; Domènech E;
Scand J Gastroenterol; 2018 Feb; 53(2):152-157. PubMed ID: 29189092
[TBL] [Abstract][Full Text] [Related]
17. Faecal chitinase 3-like 1 is a reliable marker as accurate as faecal calprotectin in detecting endoscopic activity in adult patients with inflammatory bowel diseases.
Buisson A; Vazeille E; Minet-Quinard R; Goutte M; Bouvier D; Goutorbe F; Pereira B; Barnich N; Bommelaer G
Aliment Pharmacol Ther; 2016 May; 43(10):1069-79. PubMed ID: 26953251
[TBL] [Abstract][Full Text] [Related]
18. Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn's disease after surgery.
Wright EK; Kamm MA; De Cruz P; Hamilton AL; Ritchie KJ; Krejany EO; Leach S; Gorelik A; Liew D; Prideaux L; Lawrance IC; Andrews JM; Bampton PA; Jakobovits SL; Florin TH; Gibson PR; Debinski H; Macrae FA; Samuel D; Kronborg I; Radford-Smith G; Selby W; Johnston MJ; Woods R; Elliott PR; Bell SJ; Brown SJ; Connell WR; Day AS; Desmond PV; Gearry RB
Gastroenterology; 2015 May; 148(5):938-947.e1. PubMed ID: 25620670
[TBL] [Abstract][Full Text] [Related]
19. Does fecal calprotectin predict short-term relapse after stopping TNFα-blocking agents in inflammatory bowel disease patients in deep remission?
Molander P; Färkkilä M; Ristimäki A; Salminen K; Kemppainen H; Blomster T; Koskela R; Jussila A; Rautiainen H; Nissinen M; Haapamäki J; Arkkila P; Nieminen U; Kuisma J; Punkkinen J; Kolho KL; Mustonen H; Sipponen T
J Crohns Colitis; 2015 Jan; 9(1):33-40. PubMed ID: 25052347
[TBL] [Abstract][Full Text] [Related]
20. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse.
Gisbert JP; Bermejo F; Pérez-Calle JL; Taxonera C; Vera I; McNicholl AG; Algaba A; López P; López-Palacios N; Calvo M; González-Lama Y; Carneros JA; Velasco M; Maté J
Inflamm Bowel Dis; 2009 Aug; 15(8):1190-8. PubMed ID: 19291780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
